202 related articles for article (PubMed ID: 31157865)
1. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
[TBL] [Abstract][Full Text] [Related]
2. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
4. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
[TBL] [Abstract][Full Text] [Related]
6. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
Schachtner T; Stein M; Reinke P
Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
[TBL] [Abstract][Full Text] [Related]
7. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
[TBL] [Abstract][Full Text] [Related]
8. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
11. The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation.
Stranavova L; Hruba P; Girmanova E; Tycova I; Slavcev A; Fronek J; Slatinska J; Reinke P; Volk HD; Viklicky O
Physiol Res; 2018 May; 67(2):251-260. PubMed ID: 29303612
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
13. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus.
Havenith SH; Remmerswaal EB; Bemelman FJ; Yong SL; van Donselaar-van der Pant KA; van Lier RA; Ten Berge IJ
Clin Exp Immunol; 2012 Sep; 169(3):292-301. PubMed ID: 22861369
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
15. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation.
Páez-Vega A; Cantisán S; Agüera ML; Suñer M; Facundo C; Yuste JR; Fernández-Ruiz M; Montejo M; Redondo-Pachón D; López-Oliva MO; Fernández-Rodríguez A; Fariñas MC; Hernández D; Len O; Muñoz P; Valle-Arroyo J; Rodelo-Haad C; Cordero E; Torre-Cisneros J
J Infect Dis; 2021 Apr; 223(7):1205-1213. PubMed ID: 32779713
[TBL] [Abstract][Full Text] [Related]
16. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.
Jarque M; Crespo E; Melilli E; Gutiérrez A; Moreso F; Guirado L; Revuelta I; Montero N; Torras J; Riera L; Meneghini M; Taco O; Manonelles A; Paul J; Seron D; Facundo C; Cruzado JM; Gil Vernet S; Grinyó JM; Bestard O
Clin Infect Dis; 2020 Dec; 71(9):2375-2385. PubMed ID: 32076718
[TBL] [Abstract][Full Text] [Related]
17. Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience.
Jalalonmuhali M; Ng KP; Ong CS; Lee YW; Wan Md Adnan WAH; Lim SK
Transplant Proc; 2020; 52(6):1709-1714. PubMed ID: 32448669
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
Fernández-Ruiz M; Rodríguez-Goncer I; Parra P; Ruiz-Merlo T; Corbella L; López-Medrano F; Polanco N; González E; San Juan R; Folgueira MD; Andrés A; Aguado JM
Am J Transplant; 2020 Aug; 20(8):2070-2080. PubMed ID: 31991045
[TBL] [Abstract][Full Text] [Related]
19. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents.
Fernández-Ruiz M; García-Ríos E; Redondo N; Rodríguez-Goncer I; Ruiz-Merlo T; Parra P; Sandonis V; López-Medrano F; San Juan R; González E; Polanco N; Andrés A; Navarro D; Aguado JM; Pérez-Romero P
J Infect Dis; 2024 Jun; 229(6):1812-1816. PubMed ID: 37740549
[TBL] [Abstract][Full Text] [Related]
20. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study.
de Paula MI; Bowring MG; Shaffer AA; Garonzik-Wang J; Bessa AB; Felipe CR; Cristelli MP; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
Transpl Int; 2021 Feb; 34(2):339-352. PubMed ID: 33314321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
